BACKGROUND: (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography ((PET) safely predicts axillary status in patients with breast cancer, but is not sufficiently accurate in early breast cancer patients. This study analyzed the value of (18)F-FDG PET/computed tomography (CT) with contrast enhancement in detecting axillary lymph node involvement in T1 breast cancer patients. METHODS: Contrast-enhanced (18)F-FDG PET/CT was performed within 20 days of surgery in 143 breast cancer patients with tumors ≤2 cm in size. The patients underwent either axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB), and histopathology reports were used to provide the definitive diagnosis against which the contrast-enhanced (18)F-FDG PET/CT study results were compared. RESULTS: The sensitivity, specificity, and negative and positive predictive values of contrast-enhanced (18)F-FDG PET/CT in detecting axillary involvement were 70.0%, 92.2%, 88.8%, and 77.8%, respectively, in the entire series of 143 patients, with eight false-positive and 12 false negative results. The false-negative results were associated with the number of metastatic lymph nodes and the rate of FDG uptake. CONCLUSION: Contrast-enhanced (18)F-FDG PET/CT cannot replace histologic staging using SLNB in patients with breast cancer, but (18)F-FDG PET/CT increases the sensitivity for predicting axillary node metastasis, and allows for a selective approach to either ALND or SLNB, even in patients with T1 breast cancer.
BACKGROUND: (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography ((PET) safely predicts axillary status in patients with breast cancer, but is not sufficiently accurate in early breast cancerpatients. This study analyzed the value of (18)F-FDG PET/computed tomography (CT) with contrast enhancement in detecting axillary lymph node involvement in T1 breast cancerpatients. METHODS: Contrast-enhanced (18)F-FDG PET/CT was performed within 20 days of surgery in 143 breast cancerpatients with tumors ≤2 cm in size. The patients underwent either axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB), and histopathology reports were used to provide the definitive diagnosis against which the contrast-enhanced (18)F-FDG PET/CT study results were compared. RESULTS: The sensitivity, specificity, and negative and positive predictive values of contrast-enhanced (18)F-FDG PET/CT in detecting axillary involvement were 70.0%, 92.2%, 88.8%, and 77.8%, respectively, in the entire series of 143 patients, with eight false-positive and 12 false negative results. The false-negative results were associated with the number of metastatic lymph nodes and the rate of FDG uptake. CONCLUSION: Contrast-enhanced (18)F-FDG PET/CT cannot replace histologic staging using SLNB in patients with breast cancer, but (18)F-FDG PET/CT increases the sensitivity for predicting axillary node metastasis, and allows for a selective approach to either ALND or SLNB, even in patients with T1 breast cancer.
Entities:
Keywords:
Axillary lymph node; Breast cancer; FDG; PET/CT
Authors: H M Zhuang; A Cortés-Blanco; M Pourdehnad; L E Adam; A J Yamamoto; R Martínez-Lázaro; J H Lee; J C Loman; M D Rossman; A Alavi Journal: Nucl Med Commun Date: 2001-10 Impact factor: 1.690
Authors: N Avril; C A Rosé; M Schelling; J Dose; W Kuhn; S Bense; W Weber; S Ziegler; H Graeff; M Schwaiger Journal: J Clin Oncol Date: 2000-10-15 Impact factor: 44.544
Authors: U Veronesi; C De Cicco; V E Galimberti; J R Fernandez; N Rotmensz; G Viale; G Spano; A Luini; M Intra; P Veronesi; A Berrettini; G Paganelli Journal: Ann Oncol Date: 2006-12-12 Impact factor: 32.976
Authors: I C Smith; K N Ogston; P Whitford; F W Smith; P Sharp; M Norton; I D Miller; A K Ah-See; S D Heys; J A Jibril; O Eremin Journal: Ann Surg Date: 1998-08 Impact factor: 12.969
Authors: David N Danforth; Luigi Aloj; Jorge A Carrasquillo; Stephen L Bacharach; Cathy Chow; JoAnne Zujewski; Millie Whatley; Barbara Galen; Maria Merino; Ronald D Neumann Journal: Breast Cancer Res Treat Date: 2002-09 Impact factor: 4.872
Authors: L P Adler; H F Blair; J T Makley; R P Williams; M J Joyce; G Leisure; N al-Kaisi; F Miraldi Journal: J Nucl Med Date: 1991-08 Impact factor: 10.057